



(51) International Patent Classification:
C12N 9/22 (2006.01) *C07K 14/705* (2006.01)
C12N 15/62 (2006.01) *A61K 48/00* (2006.01)
C12N 15/85 (2006.01)

(21) International Application Number:
PCT/US2017/024951

(22) International Filing Date:
30 March 2017 (30.03.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/315,480 30 March 2016 (30.03.2016) US

(71) Applicant: SPARK THERAPEUTICS, INC. [US/US];
3737 Market Street, Suite 1300, Philadelphia,
Pennsylvania 19104 (US).

(72) Inventors: ZHOU, Jingmin; 203 Glendale Road, Walling-
ford, Pennsylvania 19086 (US). QU, Guang; 22 Beaver
Dam Drive, Sicklerville, New Jersey 08081 (US).
WRIGHT, John Fraser; 68 River Birch Circle, Princeton,
New Jersey 08540 (US).

(74) Agent: BEDGOOD, Robert M.; PILLSBURY WIN-
THROP SHAW PITTMAN LLP, P.O. BOX 10500,
McLean, Virginia 22102 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,


[Continued on next page]

(54) Title: CELL LINE FOR RECOMBINANT PROTEIN AND/OR VIRAL VECTOR PRODUCTION

FIG. 2

Packaging cell line based production system

- A novel parental cell lines (DHFR^{-/-}; GS^{-/-}) created.
- Clones containing multi-thousand rAAV-genomes isolated.
- rAAV productivity is comparable to current RB productivity
- Cell clones are stable on vector production



(57) Abstract: Cells and cell lines are disclosed that are able to produce therapeutic proteins, antibodies, vectors, and viral vectors such as lentiviral vectors and adeno-associated viral (AAV) vectors. The cells and/or cell lines can have mutations or deletions in either one or both of the endogenous dihydrofolate reductase (DHFR^{-/-}) or glutamine synthetase (GS^{-/-}) genes such that DHFR and/or GS expression or function is substantially reduced or eliminated.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *of inventorship (Rule 4.17(iv))*

Declarations under Rule 4.17:

Published:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *with international search report (Art. 21(3))*